BioCentury
ARTICLE | Clinical News

Omeros' OMS721 underwhelms in Phase II for IgA nephropathy

October 5, 2018 8:24 PM UTC

Omeros Corp. (NASDAQ:OMER) reported data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721 for 12 weeks led to a 0.4% greater reduction in median proteinuria vs. placebo (18.4% vs. 18%).

The Phase II trial enrolled a cohort of 12 IgA nephropathy patients at high risk of progression who did not receive corticosteroid treatment for the three months prior to screening or during the study, and who were on a stable, optimized dose of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker. Omeros said one patient who received OMS721 whose proteinuria level remained elevated after the initial 12-week treatment course had a 67.8% reduction from baseline following an additional course of OMS721...

BCIQ Company Profiles

Omeros Corp.